Source comparison
MK-677 vs Tesamorelin + Ipamorelin Blend: Research Application Comparison
Mechanism Oral ghrelin receptor agonist; continuous GHSR1a activation Dual GHRH analog + selective ghrelin agonist; pulsatile pituitary stimulation MK-677 = steady-state GH; Blend = physiological pulses Half-Life 24+ hours (once-daily dosing) Tesamorelin ~50 m
This comparison does not assign a generated winner or score.
- Mechanism
- Oral ghrelin receptor agonist; continuous GHSR1a activation
- Dual GHRH analog + selective ghrelin agonist; pulsatile pituitary stimulation
- MK-677 = steady-state GH; Blend = physiological pulses
- Half-Life
- 24+ hours (once-daily dosing)
- Tesamorelin ~50 min, Ipamorelin ~2 hours
- Blend clears quickly; MK-677 maintains serum levels
- IGF-1 Kinetics
- Gradual accumulation; peak at 14–21 days
- Pulsatile spikes; peak 4–6 hours post-dose
- MK-677 = sustained anabolism; Blend = acute lipolysis
- Insulin Sensitivity
- Moderate impairment risk after 12+ weeks
- Minimal impact on HOMA-IR or HbA1c
- Blend preserves glucose metabolism better
- Administration
- Oral, once daily; no reconstitution required
- Subcutaneous injection; requires refrigeration 2–8°C
- MK-677 wins on convenience; Blend requires cold chain
- Receptor Downregulation
- 30–50% reduced response after 8–12 weeks without cycling
- Minimal downregulation due to pulsatile dosing
- Blend maintains pituitary sensitivity longer
- Lipolytic Efficacy
- Moderate; continuous low-level hormone-sensitive lipase activation
- High; acute GH spikes mobilize visceral fat more effectively
- Blend superior for fat metabolism studies
- Stability
- Room-temperature stable for 12+ months
- 28-day refrigerated shelf life post-reconstitution
- MK-677 = logistically simpler for long studies